Find substance use treatment options here:
- US Department of Health & Human Services  - FindTreatment.gov

Additional comprehensive US-based resources for substance use are listed below:
- National Institutes of Health - The Helping to End Addiction Long-term® Initiative

- National Institute on Drug Abuse

- US Department of Health & Human Services - Overdose Prevention Strategy

- Substance Abuse and Mental Health Services Administration (SAMHSA)

- Learn more about naloxone and where to get it

- National overdose detection and prevention hotlines - free, available 24-hours a day, 7 days a week:
• SafeSpot (800-972-0590)
• Never Use Alone (800-484-3731 or 877-696-1996)

Graphic credit: New York City Department of Health and Mental Hygiene — view full using drugs in extreme heat resource palm card here.

The 4th of July weekend is expected to bring record-breaking heat across much of the United States, with many communities already experiencing extreme temperatures. These conditions may contribute to an increase in overdose risk, as people who use drugs are more vulnerable to heat-related illness and other adverse health effects during periods of extreme heat.

Graphic credit: Philadelphia Department of Public Health — view full resource on heat safety and overdose prevention here.

Additional information:
-  A 2025 article published by researchers at Yale's School of Public Health highlights the association between extreme heat and increased drug overdose mortality.

- On July 1, Madison & Dane County Public Health in Wisconsin issued an alert following an increase in overdoses reported between June 29-30. Officials noted that the spike may have been related to extreme heat conditions.

- An article published by KJZZ on July 2nd reported that July is historically the month with the highest number of fatal overdoses in Maricopa County, Arizona; noting that substance use was a contributing factor in more than half of the county's heat-related deaths reported last year. 

📅 Date: Thursday, July 14, 2026

🕑 Time: 12:00 pm - 1:00 pm ET

📍 Location: Virtual via Zoom

Learning Objectives:
1. To describe the goals and objectives of the national drug early warning system.

2. To describe the methods used and to discuss ways to integrate data from multiple sources to better understand signals and trends of use.

3. To identify the most recent data available on new drug threats with a particular focus on fentanyl adulterants.

Register here.

As gabapentin prescribing has doubled over the past decade, its nonmedical use has risen in parallel, primarily in people with opioid use disorder. Yet the assumptions driving both clinical practice and scheduling policy have largely outpaced the evidence. This webinar presents data from multiple studies spanning national surveillance surveys, Medicaid claims, urine drug testing data, and clinical interviews that together reframe the gabapentin problem and moves us forward toward understanding the role of gabapentin as friend or foe in the ongoing opioid crisis.

📅 Date: Thursday, July 30, 2026

🕑 Time: 1:00 pm - 2:00 pm ET

📍 Location: Virtual via Zoom

Register here.

Are you committed to advancing the science of substance use and public health? The University of Florida’s NIDA-funded T32 Training Program offers predoctoral and postdoctoral scholars an exceptional opportunity to launch impactful research careers focused on NDEWS!

What We Offer:
- Interdisciplinary training at the intersection of addiction science, epidemiology, and surveillance
- Mentorship from leading UF faculty in epidemiology, public health, psychology, medicine, and more
- Hands-on research with landmark and important NIH-funded projects and access to rich data
- Career development support, including grant writing, publishing, and professional networking
- A collaborative, inclusive research community committed to reducing the burden of substance use

Eligibility:
- US citizens or permanent residents
- Interested in a PhD in Epidemiology, or early-stage postdoctoral fellows
- Demonstrated interest in substance use, addiction, or public health research

Location: Gainesville, Florida — a dynamic hub for scientific innovation with high quality of life and low cost of living.

The NDEWS Weekly Briefing curates emerging data and findings from across the Early Warning Network, which includes three core components: our Scientific Advisory Group (SAG), comprised of national experts and federal partners; our Sentinel Site Directors (SSDs), who lead local surveillance in key geographic regions; and our Community-Based Health Experts, who provide on-the-ground insights from populations most impacted by drug trends. Together, these contributors generate timely, multidisciplinary and impactful information, ranging from peer-reviewed research findings to local surveillance data. These contributions inform public health and research communities.

You can share the NDEWS Weekly Briefing with friends, colleagues, and others who would benefit from information on recent and relevant news, articles, and data related to novel drug trends in the US and globally by clicking here.

Share your research, news, and events through our submission form.

Share information on drug trends in your community through our get involved form.
Share your comments on our newsletter through our feedback form.

For more information on NDEWS' efforts, visit our website.

Follow NDEWS on Twitter/X: @NDEWSnews

If you miss or want to learn more about NDEWS Original Content, you can find our archived content on the NDEWS website:

     • NDEWS Hotspot Alerts using substance-related EMS data
     • NDEWS Rapid Street Reporting (RSR) survey data reports
     • NDEWS Web Monitoring Team Reddit Alerts
     • NDEWS Sentinel Site Reports
     • Previous issues of the NDEWS Weekly Briefings

The Weekly Briefing is a newsletter published each week by the National Drug Early Warning System (NDEWS) Coordinating Center, which is funded by the National Institute on Drug Abuse (U01DA051126) to the University of Florida (MPI: Cottler (contact), Co-Is: Goldberger, Nixon, Striley), NYU Langone Health (MPI: Palamar), and Florida Atlantic University (Co-I: Barenholtz). Any item may be reproduced provided the source is acknowledged.